FDA Brief

Warning letters Drugs

FDA warning letter to

Tan Alize Kozmetik Ve Temizlik Urunleri

High riskIssued Aug 3, 2023Posted Aug 8, 2023Center for Drug Evaluation and Research | CDER

FDA warns Turkish OTC drug maker Tan Alize over missing glycerin identity testing and a weak quality unit; import alert issued.

What happened

FDA reviewed records the firm sent in response to an April 13, 2023 request for records under section 704(a)(4) of the FD&C Act (a written demand for documents, not an inspection). The records showed the firm did not test each incoming lot of high-risk components such as glycerin for identity, including the USP test that detects diethylene glycol (DEG) and ethylene glycol (EG). FDA also found the quality unit did not use its authority to approve or reject components. FDA placed the firm on Import Alert 66-40 on June 23, 2023.

What FDA found

  1. The firm did not run at least one identity test on each shipment of each lot of incoming ingredients, including glycerin and other components at high risk of DEG or EG contamination.

    21 CFR 211.84(d)(1)
  2. The quality unit did not effectively use its responsibility and authority to approve or reject components, containers, closures, and other materials.

    21 CFR 211.22(a)

What FDA wants

FDA asks the firm to reply in writing within 30 working days describing corrections, and to send DEG and EG test results within 30 calendar days plus a risk assessment covering products still within expiry, with customer notifications and recalls if any lot is contaminated. FDA also recommends hiring a qualified CGMP consultant to audit the whole operation.

Who should pay attention

  • brands and distributors that buy OTC drug products from this Turkish manufacturer
  • US importers of OTC drugs and sunscreens
  • quality teams at any drug maker using glycerin or other high-risk components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  2. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  3. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  4. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk